# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 71-80 of 614 results.
CB-839 in Combination With Niraparib in Platinum Resistant Breast Cancer (BRCA) -Wild-type Ovarian Cancer Patients
Status: Not yet recruiting
Last Changed: Nov 25, 2019
First Received: May 10, 2019
Disease(s): Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer
Intervention(s): Cohort 1: Dose Escalation, Cohort 2: Dose Escalation
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Dec 03, 2019
First Received: Nov 08, 2018
Disease(s): Ovarian Cancer Recurrent
Intervention(s): Rintatolimod, Pembrolizumab, Cisplatin
Locations: Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
Status: Recruiting
Last Changed: Jan 14, 2020
First Received: Mar 29, 2018
Disease(s): Ovarian Cancer Prevention
Intervention(s): Acetylsalicylic acid, Placebo
Locations: Prince of Wales Hospital, Randwick, New South Wales, Australia
Peter McCallum Cancer Institute, Melbourne, Victoria, Australia
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
CancerCare Manitoba, Winnipeg, Manitoba, Canada
... and 9 other locations.
A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
Status: Recruiting
Last Changed: Dec 20, 2019
First Received: Apr 11, 2017
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Active Comparator: Olaparib tablets, Placebo
Locations: Research Site, Brussels, Belgium
Research Site, Leuven, Belgium
Research Site, Liège, Belgium
Research Site, Namur, Belgium
Research Site, London, Ontario, Canada
... and 101 other locations.
Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.
Status: Recruiting
Last Changed: Dec 12, 2019
First Received: Jan 19, 2015
Disease(s): Ovarian Cancer
Intervention(s): BRCA genetic data
Locations: Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Oct 02, 2018
Disease(s): Epithelial Ovarian Cancer
Intervention(s): anti-Mesothelin Car NK Cells
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Status: Recruiting
Last Changed: Nov 04, 2019
First Received: Oct 04, 2007
Disease(s): Ovarian Cancer
Intervention(s): Questionnaire
Locations: Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine, Miami, Florida, United States
John Stoddard Cancer Center, Des Moines, Iowa, United States
Carol G. Simon Cancer Center / Atlantic Health, Morristown, New Jersey, United States
University of Rochester Medical Center, Rochester, New York, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
... and 7 other locations.
Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
Status: Recruiting
Last Changed: May 14, 2019
First Received: Mar 18, 2019
Disease(s): Advanced Ovarian Cancer
Intervention(s): 2X-121, 2X-121 DRP®
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Aug 07, 2018
First Received: Aug 07, 2018
Disease(s): Recurrent Ovarian Cancer
Intervention(s): Involved-field radiotherapy
Locations: Severance Hospital, Seoul, Korea, Korea, Republic of
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
Status: Recruiting
Last Changed: Aug 03, 2018
First Received: Aug 03, 2018
Disease(s): Ovarian Cancer
Locations: Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
Peking Union Medical College Hospital, Beijing, China
... and 2 other locations.